Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athersys, Inc. - Common Stock (NQ: ATHX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 17, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Athersys, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Athersys to Host a Virtual Presentation on Its MultiStem® Programs
From Athersys, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Idera Pharmaceuticals (NASDAQ:IDRA) stock rose 13.0% to $0.71 during Friday's pre-market session. The market value of their outstanding shares is at $37.7... 
Via Benzinga
Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive Officer
From Athersys, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers TCR2 Therapeutics (NASDAQ:TCRR) s... 
Via Benzinga
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Athersys Shares Jump After MultiStem Cell Therapy Data Published In Medical Journal
Athersys Inc (NASDAQ: ATHX) announced that a manuscript reporting data from its MUST-ARDS clinical trial have been published in the peer-reviewed medical journal,... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're starting off Tuesday with a breakdown of the biggest pre-market stock movers you need to know about! 
Via InvestorPlace
Exposures Product Safety
Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine
From Athersys, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares... 
Via Benzinga
Athersys (ATHX) Q3 2021 Earnings Call Transcript
ATHX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Athersys Reports Third Quarter 2021 Results and Provides Corporate Update
From Athersys, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're kicking off the final day of the trading week with an overview of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K.
From Athersys
Via Business Wire
Athersys to Host Third Quarter Financial Results Call
From Athersys, Inc.
Via Business Wire
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Athersys to Present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference
From Athersys, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
How Aging-Related Conditions Are Increasing The Treatment Burden For Older Patients
Via FinancialNewsMedia
Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke
From Athersys, Inc.
Via Business Wire
Athersys (ATHX) Q2 2021 Earnings Call Transcript
ATHX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Athersys: Q2 Earnings Insights
Shares of Athersys (NASDAQ:ATHX) increased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% over the... 
Via Benzinga
Athersys Reports Second Quarter 2021 Results
From Athersys, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.